cyclophosphamide + indomethacin + methotrexate + prednisolone

This is a combination regimen consisting of four drugs—cyclophosphamide, indomethacin, methotrexate, and prednisolone. Each component has a distinct mechanism of action: - Cyclophosphamide is an alkylating agent that crosslinks DNA, leading to cell death; it is used as an antineoplastic and immunosuppressive agent[4][8]. - Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX), reducing prostaglandin synthesis and thus inflammation and pain[7]. - Methotrexate is an antimetabolite and antifolate agent that inhibits dihydrofolate reductase, suppressing DNA synthesis in rapidly dividing cells; it also exerts anti-inflammatory effects by increasing adenosine levels[5][2][8]. - Prednisolone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties through modulation of gene expression via the glucocorticoid receptor[2]. This combination may be considered for severe autoimmune or inflammatory diseases where multiple mechanisms are targeted to control disease activity. However, this specific four-drug combination does not correspond to any widely recognized branded regimen or standard protocol in current clinical practice.